Why Telix Pharmaceuticals Limited’s (TLX) Stock Is Down 5.83%
As of Thursday, October 22, Telix Pharmaceuticals Limited’s TLX share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Cynthia McLaughlin
Omar Beirat
Michael Rose
Jenna Brashear
| Share Statistics | TLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,134.9 | $211.8 | 61% |
|
| Shares Out (Mil) | 356.9 | 55.4 | 84% |
|
| Institutional Ownership | 84.5% | 93.0% | 52% |
|
| Float (Mil) | 298.0 | 41.5 | 79% |
|
| Beta | 0.60 | 0.99 | 34% |
|
| Avg Daily Volume (000s) | 282 | 553 | 49% |
|
| Price Change (52-week) |
(5.9%) | 42.8% | 46% |
|
| Growth | TLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 188.8% | 13.2% | 100% |
|
| Net Income (5yr) | 27.1% | (10.3%) | 82% |
|
| EPS (5yr) | 31.1% | 15.8% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.4%) | (15.7%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $891 | $41 | 48% |
|
| Net Income (TTM) (Mil) | $34 | ($44) | 51% |
|
| EPS (TTM) | $0.098 | ($1.500) | 43% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($35) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $45 | $-0 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $564 | $4 | 60% |
|
| Enterprise Value (Q1) (Mil) | $4,132 | $147 | 60% |
|
| Valuation | TLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.41 | 2.01 | 85% |
|
| P/E | 97.2 | 17.9 | 94% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.1 | 1.0 | 80% |
|
| Ratios | TLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.6% | 67.9% | 59% |
|
| Net Margin | 3.8% | (50.6%) | 43% |
|
| ROA | 2.6% | (47.4%) | 58% |
|
| ROE | 7.4% | (53.1%) | 48% |
|
| Liabilities to Assets | 64.2% | 29.7% | 60% |
|
| F-Score | 4 | 3 | 34% |
|
Telix Pharmaceuticals Limited did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors